Picture of Nykode Therapeutics ASA logo

NYKD — Nykode Therapeutics ASA News Story

0.000.00%
no flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapMomentum Trap

Brief: Nykode Therapeutics Announces Positive Results From Phase 1/2 Open Label, Dose Escalation Trial Of SARS-CoV-2 Vaccine Candidate

Sept 27 (Reuters) - Nykode Therapeutics Asa  NYKD.OL :
    * NYKODE THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM THE
PHASE
1/2 OPEN LABEL, DOSE ESCALATION TRIAL OF ITS T CELL FOCUSED
SARS-COV-2 VACCINE CANDIDATE
    * NYKODE'S VACCINE CANDIDATE WAS SAFE AND WELL-TOLERATED AT
ALL
THREE DOSE LEVELS
    * NYKODE-CANDIDATE IS EXPECTED TO RETAIN EFFICACY
INDEPENDENT OF
FUTURE SPIKE MUTATIONS,WOULD NOT NEED TO BE UPDATED FOR FUTURE
VARIANTS OF CONCERN

Source text for Eikon:  ID:nGNX6XmhVH 
Further company coverage:  NYKD.OL 
 ((Reuters.Briefs@thomsonreuters.com;))

Recent news on Nykode Therapeutics ASA

See all news